220
Participants
Start Date
September 30, 2009
Primary Completion Date
January 31, 2012
ranibizumab
three initial monthly intra vitreal injections with 0.5 mg ranibizumab
triamcinolone acetonide
at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
sham
at baseline one sham-injection
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Leiden University Medical Center
OTHER